Our country medicine enterprise mergers and acquisitions of financial risk and its prevention
Abstract
With the integration of the global economy, mergers and acquisitions play an increasingly important role in China's economic development. Pharmaceutical industry as one of the foundations of the people's livelihood security, the status quo of China's pharmaceutical industry as a whole is more than the number of enterprises, small scale, weak R & D capabilities, and low market share, after a series of large-scale mergers and acquisitions will help the pharmaceutical industry in China out of the current plight of scattered resources and low competitiveness. Various statistical studies show that the failure rate of mergers and acquisitions of pharmaceutical companies in China have been high. Therefore, the pharmaceutical enterprises M & A risk analysis and risk prevention strategies based on pharmaceutical enterprises in China will help to avoid M & A risk and improve the success rate of mergers and acquisitions, so as to enhance the overall competitiveness of China's pharmaceutical enterprises. This paper first introduces the overview of the mergers and acquisitions of financial risk. Second, the analysis of the basic status of China's pharmaceutical mergers and acquisitions. Including the development status of China's pharmaceutical enterprises, development prospects and acquisitions of the status quo of three parts. Third, it summarizes the performance of China's pharmaceutical mergers and acquisitions of financial risks. Fourth, the financial risk of China's pharmaceutical mergers and acquisitions precautions. Finally, the concluding section concludes the paper and come to the conclusion of the study.
